Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies.
Inflammation contributes to growth failure associated with inflammatory bowel diseases. Anti-TNFα therapy induces sustained remission and short-term improvements in height velocity and/or height standard deviation score (H-SDS) patients with Crohn's disease. The purpose of this study was to eva...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5026336?pdf=render |
| _version_ | 1818301926018646016 |
|---|---|
| author | Sarah Bamberger Christine Martinez Vinson Damir Mohamed Jérôme Viala Jean-Claude Carel Jean-Pierre Hugot Dominique Simon |
| author_facet | Sarah Bamberger Christine Martinez Vinson Damir Mohamed Jérôme Viala Jean-Claude Carel Jean-Pierre Hugot Dominique Simon |
| author_sort | Sarah Bamberger |
| collection | DOAJ |
| description | Inflammation contributes to growth failure associated with inflammatory bowel diseases. Anti-TNFα therapy induces sustained remission and short-term improvements in height velocity and/or height standard deviation score (H-SDS) patients with Crohn's disease. The purpose of this study was to evaluate growth and adult height in patients with Crohn's disease taking maintenance infliximab or adalimumab therapy.This university-hospital based retrospective study included 61 patients, with a median follow-up of 2.6 years (2.0; 3.3). 38 patients (62%) reached their adult height. H-SDS was collected at diagnosis and together with disease activity markers (Harvey-Bradshaw Index, albumin, and C-reactive protein) at treatment initiation (baseline), and follow-up completion. Wilcoxon's signed-rank test was chosen for comparisons. Median H-SDS decreased from diagnosis to baseline (-0.08 [-0.73; +0.77] to -0.94 [-1.44; +0.11], p<0.0001) and then increased to follow-up completion (-0.63 [-1.08; 0.49], p = 0.003 versus baseline), concomitantly with an improvement in disease activity. Median adult H-SDS was within the normal range (-0.72 [-1.25; +0.42]) but did not differ from baseline H-SDS and was significantly lower than the target H-SDS (-0.09 [-0.67; +0.42], p = 0.01). Only 2 (6%) males had adult heights significantly below their target heights (10.5 and -13.5 cm [-1.75 and -2.25 SD]). In conclusion, anti-tumor necrosis factor α (TNF) therapy prevented loss of height without fully restoring the genetic growth potential in this group of patients with CD. Earlier treatment initiation might improve growth outcomes in these patients. |
| first_indexed | 2024-12-13T05:30:46Z |
| format | Article |
| id | doaj.art-e1fbf34641924c78ae422c702fd34f44 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T05:30:46Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-e1fbf34641924c78ae422c702fd34f442022-12-21T23:58:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01119e016312610.1371/journal.pone.0163126Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies.Sarah BambergerChristine Martinez VinsonDamir MohamedJérôme VialaJean-Claude CarelJean-Pierre HugotDominique SimonInflammation contributes to growth failure associated with inflammatory bowel diseases. Anti-TNFα therapy induces sustained remission and short-term improvements in height velocity and/or height standard deviation score (H-SDS) patients with Crohn's disease. The purpose of this study was to evaluate growth and adult height in patients with Crohn's disease taking maintenance infliximab or adalimumab therapy.This university-hospital based retrospective study included 61 patients, with a median follow-up of 2.6 years (2.0; 3.3). 38 patients (62%) reached their adult height. H-SDS was collected at diagnosis and together with disease activity markers (Harvey-Bradshaw Index, albumin, and C-reactive protein) at treatment initiation (baseline), and follow-up completion. Wilcoxon's signed-rank test was chosen for comparisons. Median H-SDS decreased from diagnosis to baseline (-0.08 [-0.73; +0.77] to -0.94 [-1.44; +0.11], p<0.0001) and then increased to follow-up completion (-0.63 [-1.08; 0.49], p = 0.003 versus baseline), concomitantly with an improvement in disease activity. Median adult H-SDS was within the normal range (-0.72 [-1.25; +0.42]) but did not differ from baseline H-SDS and was significantly lower than the target H-SDS (-0.09 [-0.67; +0.42], p = 0.01). Only 2 (6%) males had adult heights significantly below their target heights (10.5 and -13.5 cm [-1.75 and -2.25 SD]). In conclusion, anti-tumor necrosis factor α (TNF) therapy prevented loss of height without fully restoring the genetic growth potential in this group of patients with CD. Earlier treatment initiation might improve growth outcomes in these patients.http://europepmc.org/articles/PMC5026336?pdf=render |
| spellingShingle | Sarah Bamberger Christine Martinez Vinson Damir Mohamed Jérôme Viala Jean-Claude Carel Jean-Pierre Hugot Dominique Simon Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies. PLoS ONE |
| title | Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies. |
| title_full | Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies. |
| title_fullStr | Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies. |
| title_full_unstemmed | Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies. |
| title_short | Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies. |
| title_sort | growth and adult height in patients with crohn s disease treated with anti tumor necrosis factor α antibodies |
| url | http://europepmc.org/articles/PMC5026336?pdf=render |
| work_keys_str_mv | AT sarahbamberger growthandadultheightinpatientswithcrohnsdiseasetreatedwithantitumornecrosisfactoraantibodies AT christinemartinezvinson growthandadultheightinpatientswithcrohnsdiseasetreatedwithantitumornecrosisfactoraantibodies AT damirmohamed growthandadultheightinpatientswithcrohnsdiseasetreatedwithantitumornecrosisfactoraantibodies AT jeromeviala growthandadultheightinpatientswithcrohnsdiseasetreatedwithantitumornecrosisfactoraantibodies AT jeanclaudecarel growthandadultheightinpatientswithcrohnsdiseasetreatedwithantitumornecrosisfactoraantibodies AT jeanpierrehugot growthandadultheightinpatientswithcrohnsdiseasetreatedwithantitumornecrosisfactoraantibodies AT dominiquesimon growthandadultheightinpatientswithcrohnsdiseasetreatedwithantitumornecrosisfactoraantibodies |